Clonal Abundance of Tumor-Specific CD4+ T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion

Immunity

Volumn 44, Issue 1, 2016, Pages 179-193

  Malandro, Nicole ^a,b   Budhu, Sadna ^a   Kuhn, Nicholas F ^c   Liu, Cailian ^a   Murphy, Judith T ^a,b   Cortez, Czrina ^a   Zhong, Hong ^a   Yang, Xia ^a   Rizzuto, Gabrielle ^a,d   Altan Bonnet, Grégoire ^a   Merghoub, Taha ^a   Wolchok, Jedd D ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Medical Center   (United States)

^c Gerstner Sloan Kettering Graduate School of Biomedical Sciences   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITUMOR IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; EFFECTOR CELL; IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE EXHAUSTION; TH1 CELL; ANIMAL; C57BL MOUSE; CELL SEPARATION; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; TUMOR ESCAPE;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TUMOR ESCAPE;

EID: 84959063218     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.12.018     Document Type: Article

References (41)

1. +) T cell response to infection. Immunity 2007, 26:827-841.
2. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
3. Bevan M.J. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 2004, 4:595-602.
4. Blair D.A., Lefrançois L. Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells. Proc. Natl. Acad. Sci. USA 2007, 104:15045-15050.
5. Blattman J.N., Antia R., Sourdive D.J.D., Wang X., Kaech S.M., Murali-Krishna K., Altman J.D., Ahmed R. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 2002, 195:657-664.
6. Brooks D.G., Teyton L., Oldstone M.B., McGavern D.B. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J. Virol. 2005, 79:10514-10527.
7. + T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J. Exp. Med. 2010, 207:223-235.
8. + T cells in HIV infection. PLoS Pathog. 2014, 10:e1004251.
9. Burnet F.M. A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust. J. Sci. 1957, 20:67-77.
10. Burnet F.M. The Clonal Selection Theory of Acquired Immunity 1959, In Cambridge University Press, Cambridge.
11. + T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells. J. Exp. Med. 2006, 203:1045-1054.
12. Corbeau, P., and Reynes, J. (2011). Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection, Volume 117.
13. + T cell dysfunction during chronic infection. Immunity 2014, 40:289-302.
14. + T cells of different antigen/MHC specificity. J. Immunol. 2003, 171:240-246.
15. Foulds K.E., Shen H. Clonal competition inhibits the proliferation and differentiation of adoptively transferred TCR transgenic CD4 T cells in response to infection. J. Immunol. 2006, 176:3037-3043.
16. + T cell survival controlled by clonal abundance. Science 2006, 312:114-116.
17. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D.B., Lau J.S., Zhu G., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005, 65:1089-1096.
18. Houghton A.N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 1994, 180:1-4.
19. Jenkins M.K., Moon J.J. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J. Immunol. 2012, 188:4135-4140.
20. + T cell responses during chronic infection. Nat. Immunol. 2011, 12:663-671.
21. Kedl R.M., Rees W.A., Hildeman D.A., Schaefer B., Mitchell T., Kappler J., Marrack P. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 2000, 192:1105-1113.
22. + T cell proliferation and effector function in vivo. Immunity 2000, 13:291-301.
23. Lazarevic V., Glimcher L.H., Lord G.M. T-bet: a bridge between innate and adaptive immunity. Nat. Rev. Immunol. 2013, 13:777-789.
24. + T cell lineage commitment. Nat. Immunol. 2005, 6:793-799.
25. +) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007, 27:203-213.
26. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., Paulos C.M., Palmer D.C., Touloukian C.E., Ptak K., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
27. Nabavi N., Freeman G.J., Gault A., Godfrey D., Nadler L.M., Glimcher L.H. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992, 360:266-268.
28. + T cells cooperate to contain chronic viral infection. Science 2012, 338:1220-1225.
29. +) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010, 207:637-650.
30. Quiel J., Caucheteux S., Laurence A., Singh N.J., Bocharov G., Ben-Sasson S.Z., Grossman Z., Paul W.E. Antigen-stimulated CD4 T-cell expansion is inversely and log-linearly related to precursor number. Proc. Natl. Acad. Sci. USA 2011, 108:3312-3317.
31. Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 1993, 177:925-935.
32. + T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 2009, 206:849-866.
33. Smith A.L., Wikstrom M.E., Fazekas de St Groth B. Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize the effect of precursor frequency. Immunity 2000, 13:783-794.
34. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
35. Walsh K.B., Marsolais D., Welch M.J., Rosen H., Oldstone M.B.A. Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection. Virology 2010, 397:260-269.
36. + T cells. J. Immunol. 2006, 176:3028-3036.
37. Willis R.A., Kappler J.W., Marrack P.C. CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc. Natl. Acad. Sci. USA 2006, 103:12063-12068.
38. Wold S., Sjöström M., Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom. Intell. Lab. Syst. 2001, 58:109-130.
39. Xie Y., Akpinarli A., Maris C., Hipkiss E.L., Lane M., Kwon E.K., Muranski P., Restifo N.P., Antony P.A. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 2010, 207:651-667.
40. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J.D., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998, 188:2205-2213.
41. Zehn D., Bevan M.J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006, 25:261-270.